Similarly, a recent meta-analysis of RCTs showed that GLP-1 RAs were effective in preventing serious adverse cardiovascular events in T2DM patients with obesity (relative risk = 0.88, 95% CI (0.81, 0.96)), whereas SGLT2i marginally prevented serious adverse cardiovascular events (relative risk = 0.91, 95% CI (0.83, 1.00)) [62]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.